Maria Reviejo

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Impact of CD44 alternative splicing on the response to anticancer drugs.

Impact of CD44 alternative splicing on the response to anticancer drugs.

Journal: Biochemical pharmacology

Published: March 05, 2026

A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.

A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.

Journal: Journal of gastrointestinal oncology

Published: February 08, 2026

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma.

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma.

Journal: Biochemical pharmacology

Published: October 06, 2025

Role of tumor suppressor genes P53 and PTEN in CD44-mediated gastric adenocarcinoma multidrug resistance.

Role of tumor suppressor genes P53 and PTEN in CD44-mediated gastric adenocarcinoma multidrug resistance.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 13, 2025

Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events.

Impact of alternative splicing on cholangiocarcinoma progression through metabolic rewiring-induced epigenetic events.

Journal: Journal of hepatology

Published: May 12, 2024

Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.

Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.

Journal: Cancer drug resistance (Alhambra, Calif.)

Published: April 09, 2024

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Clinical pharmacology and therapeutics

Published: November 07, 2023

Impact of Alternative Splicing Variants on Liver Cancer Biology.

Impact of Alternative Splicing Variants on Liver Cancer Biology.

Journal: Cancers

Published: November 19, 2021

Impact of alternative splicing on mechanisms of resistance to anticancer drugs.

Impact of alternative splicing on mechanisms of resistance to anticancer drugs.

Journal: Biochemical pharmacology

Published: August 20, 2021

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.

Journal: Cancers

Published: June 04, 2020

What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs.

What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs.

Journal: Expert opinion on drug metabolism & toxicology

Published: June 12, 2019

Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.

Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: May 29, 2019

Showing 1-12 of 12

Last Updated: 09/26/2026